Research community previously filed under “Radiology, Nuclear Medicine and Imaging”

Targeted Radionuclide Therapy and PET Imaging for Prostate and Neuroendocrine Cancers

Mostly in the field Nuclear Medicine and Molecular Imaging for Oncology and Neurology (77% of its papers), one of 4 communities there

Papers 40,839
Elements 10
Keywords & sectors 95
Leading venue European Journal of Nuclear Medicine and Molecular Imaging

Targeted Radionuclide Therapy and PET Imaging for Prostate and Neuroendocrine Cancers

This community focuses on the development and clinical application of targeted radionuclide therapies and molecular imaging techniques, primarily for treating and diagnosing metastatic prostate cancer and neuroendocrine tumors.

The research centers on the use of specific radioligands, such as PSMA-targeted agents and peptide receptor radionuclide therapies, for both diagnostic imaging via PET and SPECT, and therapeutic intervention. Key recurring themes include the management of castration-resistant prostate cancer, the treatment of neuroendocrine tumors, and the evaluation of targeted alpha and beta-emitting radionuclides. The work involves preclinical evaluation of new radiopharmaceuticals, clinical trials assessing efficacy in patients with bone metastases, and the refinement of imaging protocols for molecular diagnostics.

The largest share of the community's output is found in lutetium research, accounting for 17.9% of all lutetium research, and 1,225 papers here. Radium research also represents a significant portion, with 1,556 papers in this community constituting 7.3% of all radium research.

The community comprises 40,839 papers, published most frequently in the European Journal of Nuclear Medicine and Molecular Imaging, the Journal of Nuclear Medicine, and Nuclear Medicine and Biology.

Recent work includes phase 3 trials evaluating the combination of Lutetium-177 PSMA-617 with androgen deprivation therapy, studies on the molecular blueprint of targeted radionuclide therapy, and consensus guidelines for standardized PSMA PET/CT analysis and reporting.

Recurring themes in the literature

Phrases that recur across this community's paper titles -- a quick map of its sub-topics, drawn straight from the titles themselves.

  • prostate cancer 3570
  • castration-resistant prostate 885
  • pet imaging 749
  • metastatic castration-resistant 722
  • radionuclide therapy 590
  • radioligand therapy 553
  • neuroendocrine tumors 459
  • nuclear medicine 452
  • breast cancer 392
  • membrane antigen 367
  • case report 361
  • molecular imaging 348
  • prostate-specific membrane 317
  • patients metastatic 313
  • cancer patients 291
  • positron emission 274
  • emission tomography 260
  • targeted alpha 249
  • alpha therapy 249
  • peptide receptor 244
  • psma pet 240
  • bone metastases 224
  • metastatic prostate 216
  • receptor radionuclide 211

Papers behind this description

Most cited
The Lancet · 2024 · 826 citations
European Urology · 2023 · 862 citations
Nature Reviews Drug Discovery · 2022 · 1141 citations
European Journal of Endocrinology · 2023 · 766 citations
Journal of the National Comprehensive Cancer Network · 2023 · 604 citations
Newest
JAMA · 2025 · 63 citations
Journal of Clinical Oncology · 2026 · 45 citations
Nature Medicine · 2025 · 52 citations
Nature Reviews Clinical Oncology · 2025 · 38 citations
Annals of Oncology · 2025 · 37 citations

A sample from the 18 papers behind this description. Create a free account to see them all.